Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02585973
Recruitment Status : Recruiting
First Posted : October 26, 2015
Last Update Posted : June 14, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

Brief Summary:
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC).

Condition or disease Intervention/treatment Phase
Carcinoma, Squamous Cell of Head and Neck Drug: AZD1775 Drug: Cisplatin Radiation: Intensity Modulated Radiotherapy Treatments Phase 1

Detailed Description:

This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC). The first cohort will include a starting dose of 50 mg AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.

Up to 24 patients will be enrolled, depending on the rate of dose limiting toxicity (DLT). The investigators plan to characterize the toxicity (and safety) profile of this regimen. Secondary objectives include determination of the recommended phase 2 dose (RP2D; based on safety and other data considerations), objective response rate (ORR) at 12 weeks and progression free survival (PFS). the investigators will also estimate overall survival (OS) if the effective sample size allows. The investigators hypothesize that the investigators' proposed regimen is safe, and will yield an improved ORR and PFS over historical controls. Correlative studies will be performed on archival tissue, and on optional fresh biopsies performed at baseline and mid-treatment. The investigators will explore associations between p53 mutational status at baseline as well as changes in checkpoint markers, with ORR, PFS and OS. Finally, the investigators plan to describe possible changes in QOL, speech and swallowing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Trial of Dose-escalating AZD1775 in Combination With Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Study Start Date : February 2016
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Arm Intervention/treatment
open label, single-arm, Phase 1b
AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
Drug: AZD1775
AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
Other Names:
  • MK-1775 hemihydrate
  • L001739996-008U

Drug: Cisplatin
40 mg/m2 IV infused over 1 hour D1 of each week of radiation
Other Name: cisplatin injection

Radiation: Intensity Modulated Radiotherapy Treatments
Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
Other Name: IMRT




Primary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: 7 weeks ]
    Estimate maximum tolerated dose of AZD1775 in combination with cisplatin plus radiotherapy


Secondary Outcome Measures :
  1. Toxicity profile (Number of patients with adverse events) [ Time Frame: 7 weeks ]
    Number of patients with adverse events

  2. Objective Response Rate [ Time Frame: 12 weeks ]
    Objective Response Rate = partial response (PR) + complete response (CR)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

4.1.1 Age ≥ 18 years of age 4.1.2 ECOG Performance Status ≤ 1 (see section 12.4, Appendix D) 4.1.3 Biopsy proven HNSCC of the oropharynx, larynx, hypopharynx, or oral cavity Stage III-IVB as defined by American Joint Committee on Cancer (AJCC) T0-T4, N0 - N3, M0 4.1.4 4.1.4 Must be considered Intermediate or High Risk

Oropharynx Intermediate risk patients include those who have all of the following:

  • HPV/p16 (+) disease, a significant tobacco smoking history (>10 pack years) and N2b-N3 disease OR
  • HPV (-) disease, ≤ 10 years of smoking and large tumors (T2-T3)

Oropharynx High risk patients include those who are either:

  • HPV (-) with >10 years of smoking, OR
  • HPV (-), ≤ 10 years of smoking and T4 disease Oral Cavity, Larynx, Hypopharynx are considered high/intermediate risk (regardless of HPV, p16 or smoking status) 4.1.5 Pre-treatment swallowing evaluation by speech and swallowing therapist, to included a modified barium swallow showing no significant impairment with swallowing oral medications.

4.1.6 Required initial laboratory values:

  • HgB ≥ 9.0 g/dL
  • ANC≥1500/mm3
  • Platelet count ≥ 100,000/mm3
  • Serum creatinine ≤1.5 mg/dL and/or calculated creatinine clearance ≥50 mL/min(via Cockroft and Gault, see section 12.2, Appendix B)
  • • Bilirubin within normal limits unless patient has Gilbert's disease and then bilirubin ≤ 3 x upper limits of normal (ULN)
  • AST and ALT ≤ 3.0 x ULN 4.1.7 No prior definitive surgery for HNSCC 4.1.8 Recommendation to undergo concurrent CRT, as determined by the treating physician, with a curative goal 4.1.9 Women of childbearing potential (WOCBP) should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study. WOCBP are those who have not been surgically sterilized or have not been free from menses for > 1 year. The two birth control methods can be composed of: two barrier methods or a barrier method plus a hormonal method to prevent pregnancy. Subjects should start using birth control from the screening visit and continue throughout study mandated treatment and for 90 days after the final dose of study drug.

The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).

4.1.10 Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy and continuing through the last dose of study therapy and for 90 days after the final dose of study drug 4.1.11 Women of childbearing potential (WOCBP) must have negative pregnancy test within 72 hours prior to D1 of treatment 4.1.12 Ability to swallow oral medications 4.1.13 As determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures for the entire length of the study 4.1.14 Informed consent reviewed and signed

Exclusion Criteria:

4.2.1 Major surgical procedures ≤28 days prior to D1 of AZD1775 or minor surgical procedures ≤7 days; no waiting required following port-a-cath placement 4.2.2 Patients who have received prior radiation therapy for HNSCC 4.2.3 4.2.3 Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 12.3, Appendix C), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.

• ECG ≤450 msec for males and ≤470 msec for females required on screening ECG 4.2.4 AST or ALT ≥3 x ULN (upper limit of normal) and total bilirubin ≥2 x ULN please refer to Appendix 12.5 'Actions required in cases of combined increase of Aminotransferase and Total Bilirubin - Hy's Law', for further instructions 4.2.5 Not deemed a candidate for concurrent CRT for medical reasons, such as uncontrolled infection (including HIV), or uncontrolled diabetes mellitus which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.

4.2.6 Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from 14 days prior to the dose of study medication, throughout the study, and until 2 weeks after the last dose of AZD1775 due to potential CYP3A4 interaction with the study medication. Orange juice is allowed.

4.2.7 Patient has had prescription or non-prescription drugs or other products (ie, grapefruit juice) known to be moderate to strong inhibitors or inducers of CYP3A4, which cannot be discontinued 14 days before Day 1 of dosing and withheld throughout the study until 14 days after the last dose of AZD1775 (see section 12.5 Appendix E). Co-administration of aprepitant and fosaprepitant during this study is prohibited. Co-treatment with weak inhibitors of CYP3A4 is allowed.

4.2.8 AZD1775 is an inhibitor of breast cancer resistance protein (BCRP). The use of statins including atorvastatin which are substrates for BCRP are therefore prohibited and patients should be moved on to non-BCRP alternatives.

4.2.9 Unable or unwilling to discontinue use of any sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic window (see section 12.5, Appendix E) 4.2.10 Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AZD1775 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) 4.2.11 Receiving or less than 21 days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent 4.2.12 Patients with a "currently active" second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, "low risk" adenocarcinoma of the prostate and carcinoma in situ of the cervix. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 2 years.

4.2.13 Pregnant or nursing


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02585973


Contacts
Layout table for location contacts
Contact: Dan Goldin 919-966-4432 dan_goldin@med.unc.edu
Contact: Chris Hilliard 919-966-4432 chris_hilliard@med.unc.edu

Locations
Layout table for location information
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Dan Goldin    919-966-4432    dan_goldin@med.unc.edu   
Contact: Chris Hilliard    919-966-4432    Chris_Hilliard@med.unc.edu   
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Bhishamjit Chera, MD University of North Carolina at Chape Hill

Additional Information:
Layout table for additonal information
Responsible Party: UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT02585973    
Other Study ID Numbers: LCCC 1430
First Posted: October 26, 2015    Key Record Dates
Last Update Posted: June 14, 2019
Last Verified: June 2019
Keywords provided by UNC Lineberger Comprehensive Cancer Center:
AZD1775
Cisplatin
Head and Neck Squamous Cell Carcinoma
HNSCC
Chemoradiotherapy
Radiotherapy
CRT
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms, Squamous Cell
Cisplatin
MK-1775
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action